Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits
October 17 2008 - 9:42AM
PR Newswire (US)
WEIFANG, Shandong, China, Oct. 17 /Xinhua-PRNewswire-FirstCall/ --
Shengtai Pharmaceutical, Inc. (OTC:SGTI) (BULLETIN BOARD: SGTI)
('Shengtai' or 'the Company'), a leading manufacturer and
distributor of high-quality, pharmaceutical grade glucose products
in China, today announced that it has completed factory
improvements providing technological and environmental best
practices in the Company's cornstarch facility. The Company's
improvement of the water treatment program in the cornstarch
production facility has resulted in a significant reduction of
protein deposits from its sewage. These technological enhancements
led to the removal of three high-power pumps and a cold water
tower, which lowered the plant's monthly electricity usage by
approximately 8,000 kWh. Additionally, higher plant efficiency was
attained through reduced labor costs and a noticeably streamlined
production facility. "These changes will improve our factory's
efficiency and provide cost reductions," said Mr. Qingtai Liu,
Chairman and CEO of Shengtai Pharmaceutical. "We are dedicated to
improving our technology and maintaining a state-of-the-art
production facility to ensure the highest-quality products for our
customers and the best environment for our workforce." About
Shengtai Pharmaceutical, Inc. Shengtai Pharmaceutical, Inc. through
its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New
Jersey corporation, and the Chinese operating company of Weifang
Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and
supplier of pharmaceutical grade glucose used for medical purposes,
and the glucose and cornstarch products for the food and beverage
industry and for industrial production in China. For more
information about Shengtai Pharmaceutical, Inc., please visit
http://www.shengtaipharmaceutical.com/ . Safe Harbor Statement Safe
Harbor Statement under the Private Securities Litigation Reform Act
of 1995: Certain statements in this press release and oral
statements made by the Company constitute forward-looking
statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. These statements
include, without limitation, statements regarding our ability to
prepare the company for growth, the Company's planned capacity
expansion in 2008 and predictions and guidance relating to the
Company's future financial performance. We have based these
forward-looking statements largely on our current expectations and
projections about future events and financial trends that we
believe may affect our financial condition, results of operations,
business strategy and financial needs but they involve risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements, which may include,
but are not limited to, such factors as unanticipated changes in
product demand especially in the pharmaceutical industry, pricing
and demand trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large scale implementation of the
company's business plan, the ability to attract new customers,
ability to increase its product's applications, cost of raw
materials, downturns in the Chinese economy, and other information
detailed from time to time in the Company's filings and future
filings with the United States Securities and Exchange Commission.
Investors are urged to consider these factors carefully in
evaluating the forward-looking statements herein and are cautioned
not to place undue reliance on such forward-looking statements,
which are qualified in their entirety by this cautionary statement.
The forward-looking statements made herein speak only as of the
date of this press release and the Company undertakes no duty to
update any forward-looking statement to conform the statement to
actual results or changes in the company's expectations. For more
information, please contact: Shengtai Pharmaceutical, Inc. Ms. Yiru
Melody Shi Chief Financial Officer Tel: +1-949-468-7078 Email:
Grayling Global Eddie Cheung Investor Relations Tel:
+1-646-284-9414 Email: DATASOURCE: Shengtai Pharmaceutical, Inc.
CONTACT: Ms. Yiru Melody Shi, Chief Financial Officer Shengtai
Pharmaceutical, Inc., +1-949-468-7078, ; or at Grayling Global,
Eddie Cheung, Investor Relations, +1-646-284-9414, , for SGTI Web
Site: http://www.shengtaipharmaceutical.com/
Copyright